Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Kallyope is a clinical-stage biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. Founded in 2015 by Charles Zuker, Tom Maniatis, and Richard Axel, Kallyope leverages a sophisticated platform that integrates advanced technologies such as sequencing, bioinformatics, cellular and molecular biology, and human genetics to identify and validate novel targets and develop gut-restricted oral small-molecule drugs. The company focuses on major unmet medical needs in areas including metabolic disorders (like obesity and diabetes), gastrointestinal conditions, and central nervous system disorders. By understanding the complex communication between the gut and the brain, Kallyope aims to create transformative medicines that act locally in the gut to achieve systemic effects with improved safety and efficacy.
The headquarters serves as the central hub for Kallyope's research and development operations, including drug discovery, translational science, clinical development, as well as corporate functions like business development, finance, and administration.
Situated in the Alexandria Center for Life Science, the facility boasts state-of-the-art laboratories, cutting-edge research equipment, and modern office spaces designed to foster collaboration and innovation. The center itself is known for its vibrant scientific community and shared amenities.
Kallyope fosters a highly collaborative, science-driven, and innovative work environment. The culture emphasizes rigorous scientific inquiry, teamwork, and a shared passion for translating groundbreaking discoveries into impactful therapies for patients. Being in NYC offers a dynamic and diverse talent pool.
The location in New York City, specifically within a premier life science campus, provides Kallyope with access to world-class academic institutions, a rich talent pool, potential collaborators, and a strong investor community, all crucial for a growing biotech company.
While Kallyope's physical operations are primarily centered in its New York City headquarters, its research and development efforts have a global outlook. The company designs clinical trials that may involve sites internationally to reach diverse patient populations and collaborates with researchers and institutions worldwide. Their therapeutic candidates are intended for global markets upon approval.
430 East 29th Street, 14th Floor
New York
NY
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Kallyope' leadership includes:
Kallyope has been backed by several prominent investors over the years, including:
Based on public announcements, Kallyope has maintained stability in its core executive team over the past 12 months, with no major C-suite hires or departures widely reported. The company continues to build out its scientific and development teams.
Discover the tools Kallyope uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Kallyope likely uses common corporate email formats. The most probable formats are [first_initial][last]@kallyope.com or [first].[last]@kallyope.com. These are standard in the biotechnology and pharmaceutical industries.
flast@kallyope.com, first.last@kallyope.com
Format
jgaleota@kallyope.com
Example
80%
Success rate
Kallyope Press Release • May 2, 2024
Kallyope announced it will present new preclinical data on its programs targeting anorexia and obesity at the Digestive Disease Week (DDW) Conference, May 18-21, 2024, in Washington D.C. The presentations will highlight novel gut-restricted compounds and their mechanisms....more
Kallyope Press Release • November 2, 2023
Kallyope announced multiple oral and poster presentations at ObesityWeek® 2023, held October 14-17 in Dallas, TX. The presentations featured new data on Kallyope’s portfolio of gut-restricted small molecules for obesity and related metabolic disorders, including programs targeting GLP-1, GIP, and GDF15 pathways....more
Kallyope Press Release • January 5, 2023
Kallyope announced the appointment of Shirly Pinto, Ph.D., as Chief Scientific Officer. Dr. Pinto brings extensive experience in drug discovery and development, particularly in neuroscience and metabolic diseases, from her previous roles at Teva Pharmaceuticals and other biotech companies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Kallyope, are just a search away.